2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary.

[1]  Silvio C. E. Tosatto,et al.  Whole-Exome Sequencing Identifies Pathogenic Variants in TJP1 Gene Associated With Arrhythmogenic Cardiomyopathy , 2018, Circulation. Genomic and precision medicine.

[2]  William J. Bryant,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2018, Circulation.

[3]  P. Hawkins,et al.  Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis , 2018, British journal of haematology.

[4]  A. Baranchuk,et al.  Arrhythmogenic right ventricular dysplasia/cardiomyopathy: an electrocardiogram-based review. , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  R. Hauer,et al.  Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) , 2018, Journal of cardiovascular electrophysiology.

[6]  T. Edvardsen,et al.  Harmful Effects of Exercise Intensity and Exercise Duration in Patients With Arrhythmogenic Cardiomyopathy. , 2018, JACC. Clinical electrophysiology.

[7]  D. Dingli,et al.  Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[8]  R. Hinton,et al.  Genetic Testing in Pediatric Left Ventricular Noncompaction , 2017, Circulation. Cardiovascular genetics.

[9]  J. Fernández-Armenta,et al.  Epicardial ablation may not be necessary in all patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and frequent ventricular tachycardia: author's reply. , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  J. Curtis,et al.  Complications Associated With Implantable Cardioverter Defibrillators in Adults With Congenital Heart Disease or Left Ventricular Noncompaction Cardiomyopathy (From the NCDR® Implantable Cardioverter-Defibrillator Registry). , 2017, The American journal of cardiology.

[11]  T. Edvardsen,et al.  Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation , 2017, European heart journal.

[12]  M. Chung,et al.  HRS Clinical Document Development Methodology Manual and Policies: Executive summary. , 2017, Heart rhythm.

[13]  W. Briggs,et al.  Prevalence and Prognostic Significance of Left Ventricular Noncompaction in Patients Referred for Cardiac Magnetic Resonance Imaging , 2017, Circulation. Cardiovascular imaging.

[14]  Dhanunjaya R. Lakkireddy,et al.  Outcomes after repeat ablation of ventricular tachycardia in structural heart disease: An analysis from the International VT Ablation Center Collaborative Group. , 2017, Heart rhythm.

[15]  H. Calkins,et al.  Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications , 2017, Journal of the American Heart Association.

[16]  M. Scheinman,et al.  Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. , 2017, Heart Rhythm.

[17]  T. Wieland,et al.  Identification of Cadherin 2 (CDH2) Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy , 2017, Circulation. Cardiovascular genetics.

[18]  D. Tester,et al.  Whole exome sequencing with genomic triangulation implicates CDH2‐encoded N‐cadherin as a novel pathogenic substrate for arrhythmogenic cardiomyopathy , 2017, Congenital heart disease.

[19]  B. Desjardins,et al.  Ventricular arrhythmias associated with left ventricular noncompaction: Electrophysiologic characteristics, mapping, and ablation. , 2017, Heart rhythm.

[20]  R. Bellazzi,et al.  Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk. , 2016, Journal of the American College of Cardiology.

[21]  L. Calò,et al.  Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. , 2016, Journal of the American College of Cardiology.

[22]  D. Andreini,et al.  Long-Term Prognostic Value of Cardiac Magnetic Resonance in Left Ventricle Noncompaction: A Prospective Multicenter Study. , 2016, Journal of the American College of Cardiology.

[23]  E. Arana-Rueda,et al.  Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[24]  T. Aiba,et al.  Potentially Lethal Ventricular Arrhythmias and Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy: What Are the Differences Between Men and Women? , 2016, JACC Clinical Electrophysiology.

[25]  D. Packer,et al.  Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis , 2016, Journal of cardiovascular electrophysiology.

[26]  P. Ponikowski,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[27]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[28]  W. Berger,et al.  Arrhythmogenic right ventricular cardiomyopathy: implications of next-generation sequencing in appropriate diagnosis , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[29]  John L Sapp,et al.  Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. , 2016, The New England journal of medicine.

[30]  J. Cigarroa,et al.  Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Circulation.

[31]  D. Panagiotakos,et al.  Arrhythmic risk assessment in genotyped families with arrhythmogenic right ventricular cardiomyopathy. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[32]  R. Hauer,et al.  Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2016, European heart journal.

[33]  D. MacArthur,et al.  Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.

[34]  R. Hauer,et al.  Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in the Pediatric Population: Clinical Characterization and Comparison With Adult-Onset Disease. , 2015, JACC. Clinical electrophysiology.

[35]  D. Lin,et al.  Long-Term Outcome With Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy , 2015, Circulation. Arrhythmia and electrophysiology.

[36]  Dhanunjaya R. Lakkireddy,et al.  Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. , 2015, Heart rhythm.

[37]  M. Link,et al.  Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2015, Circulation.

[38]  M. Link,et al.  Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement , 2015, European heart journal.

[39]  M. Link,et al.  Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. , 2015, European heart journal.

[40]  Stefan L. Zimmerman,et al.  Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members , 2015, Circulation. Cardiovascular genetics.

[41]  P. Hawkins,et al.  A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. , 2015, European heart journal.

[42]  H. Calkins,et al.  Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2015, Heart rhythm.

[43]  T. Edvardsen,et al.  Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members , 2014, European journal of heart failure.

[44]  B. Thilaganathan,et al.  Reversible De Novo Left Ventricular Trabeculations in Pregnant Women: Implications for the Diagnosis of Left Ventricular Noncompaction in Low-Risk Populations , 2014, Circulation.

[45]  R. Hauer,et al.  Outcome in Phospholamban R14del Carriers: Results of a Large Multicentre Cohort Study , 2014, Circulation. Cardiovascular genetics.

[46]  Stefan L. Zimmerman,et al.  Yield of serial evaluation in at-risk family members of patients with ARVD/C. , 2014, Journal of the American College of Cardiology.

[47]  M. Link,et al.  Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. , 2014, Journal of the American College of Cardiology.

[48]  Ashley M. Lee,et al.  Defining Left Ventricular Noncompaction Using Cardiac Computed Tomography , 2014, Journal of thoracic imaging.

[49]  C. Tracy,et al.  HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. , 2013, Heart rhythm.

[50]  Ulf Ekelund,et al.  Guide to the assessment of physical activity: Clinical and research applications: a scientific statement from the American Heart Association. , 2013, Circulation.

[51]  H. Calkins,et al.  Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[52]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[53]  A. Moss,et al.  Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). , 2013, Journal of the American College of Cardiology.

[54]  S. Russell,et al.  Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. , 2013, Journal of the American College of Cardiology.

[55]  F. Anselme,et al.  Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. , 2013, Heart rhythm.

[56]  Wataru Shimizu,et al.  HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes , 2013 .

[57]  J. Towbin,et al.  Mortality and Sudden Death in Pediatric Left Ventricular Noncompaction in a Tertiary Referral Center , 2013, Circulation.

[58]  A. Bassett,et al.  The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43 , 2013, Clinical genetics.

[59]  Paco Hulpiau,et al.  Mutations in the area composita protein αT-catenin are associated with arrhythmogenic right ventricular cardiomyopathy. , 2013, European heart journal.

[60]  R. Hauer,et al.  Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy , 2012, European journal of heart failure.

[61]  W. Stevenson,et al.  Catheter Ablation of Ventricular Tachycardia in Nonischemic Heart Disease , 2012, Circulation. Arrhythmia and electrophysiology.

[62]  M. Ashworth,et al.  Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. , 2012, European heart journal.

[63]  D. Jenne,et al.  Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy 7 is caused by a DES mutation , 2012, European Journal of Human Genetics.

[64]  A. Zwinderman,et al.  Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. , 2012, Journal of the American College of Cardiology.

[65]  D. Corrado,et al.  Clinical phenotype and diagnosis of arrhythmogenic right ventricular cardiomyopathy in pediatric patients carrying desmosomal gene mutations , 2011, Heart rhythm.

[66]  J. Finsterer,et al.  Frequency of stroke and embolism in left ventricular hypertrabeculation/noncompaction. , 2011, The American journal of cardiology.

[67]  Brian R. Anderson,et al.  Genetic Variation in Titin in Arrhythmogenic Right Ventricular Cardiomyopathy–Overlap Syndromes , 2011, Circulation.

[68]  L. Jordaens,et al.  Indications and Outcome of Implantable Cardioverter‐Defibrillators for Primary and Secondary Prophylaxis in Patients with Noncompaction Cardiomyopathy , 2011, Journal of cardiovascular electrophysiology.

[69]  David R Bassett,et al.  2011 Compendium of Physical Activities: a second update of codes and MET values. , 2011, Medicine and science in sports and exercise.

[70]  H. Calkins,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Heart rhythm.

[71]  A. Verma,et al.  Ablation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Arrhythmia-Free Survival After Endo-Epicardial Substrate Based Mapping and Ablation , 2011, Circulation. Arrhythmia and electrophysiology.

[72]  P. Elliott,et al.  Familial Evaluation in Arrhythmogenic Right Ventricular Cardiomyopathy: Impact of Genetics and Revised Task Force Criteria , 2011, Circulation.

[73]  R. Hauer,et al.  Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. , 2011, Journal of the American College of Cardiology.

[74]  L. Mestroni,et al.  Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. , 2011, European heart journal.

[75]  H. Calkins,et al.  Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease. , 2011, Heart rhythm.

[76]  Deborah A Nickerson,et al.  Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. , 2011, American journal of human genetics.

[77]  M. Link,et al.  Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia , 2010, Circulation.

[78]  F. T. ten Cate,et al.  The Importance of Genetic Counseling, DNA Diagnostics, and Cardiologic Family Screening in Left Ventricular Noncompaction Cardiomyopathy , 2010, Circulation. Cardiovascular genetics.

[79]  L. Jordaens,et al.  Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Diagnostic Task Force Criteria: Impact of New Task Force Criteria , 2010, Circulation. Arrhythmia and electrophysiology.

[80]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, European heart journal.

[81]  F. Thuny,et al.  Assessment of left ventricular non-compaction in adults: side-by-side comparison of cardiac magnetic resonance imaging with echocardiography. , 2010, Archives of cardiovascular diseases.

[82]  I. V. Van Gelder,et al.  Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. , 2009, Heart rhythm.

[83]  P. Pellikka,et al.  Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[84]  G. Marcus,et al.  Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. , 2009, Journal of the American College of Cardiology.

[85]  F. Marchlinski,et al.  Epicardial Substrate and Outcome With Epicardial Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2009, Circulation.

[86]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[87]  L. Tavazzi,et al.  Long-term outcome and risk stratification in dilated cardiolaminopathies. , 2008, Journal of the American College of Cardiology.

[88]  J. Ornato,et al.  ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2008, Heart rhythm.

[89]  Sean Connors,et al.  Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. , 2008, American journal of human genetics.

[90]  P. Elliott,et al.  Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria? , 2007, European heart journal.

[91]  J. Saffitz,et al.  A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy. , 2007, American journal of human genetics.

[92]  S. Russell,et al.  Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[93]  T. M. Yelbuz,et al.  Isolated noncompaction of the left ventricular myocardium , 2007, Clinical Research in Cardiology.

[94]  Petros Syrris,et al.  Clinical and Genetic Characterization of Families With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Provides Novel Insights Into Patterns of Disease Expression , 2007, Circulation.

[95]  P. Syrris,et al.  Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. , 2006, American journal of human genetics.

[96]  S. Russell,et al.  Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[97]  Hugh Calkins,et al.  Desmosomal Dysfunction due to Mutations in Desmoplakin Causes Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2006, Circulation research.

[98]  A. Biederman,et al.  Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2006, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[99]  Hugh Calkins,et al.  DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2006, American journal of human genetics.

[100]  Masahiko Hoshijima,et al.  Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures. , 2006, American journal of physiology. Heart and circulatory physiology.

[101]  E. Fain,et al.  Comparison of (cid:1) -Blockers, Amiodarone Plus (cid:1) -Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators The OPTIC Study: A Randomized Trial , 2005 .

[102]  Stefan Neubauer,et al.  Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. , 2005, Journal of the American College of Cardiology.

[103]  Akshay S. Desai,et al.  Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. , 2005, JAMA.

[104]  A. Bassett,et al.  The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). , 2005, Journal of the American College of Cardiology.

[105]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[106]  Akshay S. Desai,et al.  Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-analysis of Randomized Controlled Trials , 2004 .

[107]  Walter Birchmeier,et al.  Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy , 2004, Nature Genetics.

[108]  L. Mestroni,et al.  SCN5A Mutation Associated With Dilated Cardiomyopathy, Conduction Disorder, and Arrhythmia , 2004, Circulation.

[109]  X. Jouven,et al.  Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2004, Circulation.

[110]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[111]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[112]  W. Giles,et al.  Nkx2-5 Pathways and Congenital Heart Disease Loss of Ventricular Myocyte Lineage Specification Leads to Progressive Cardiomyopathy and Complete Heart Block , 2004, Cell.

[113]  Yuan-Ping Pang,et al.  ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating , 2004, Nature Genetics.

[114]  M. Link,et al.  Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2003, Circulation.

[115]  G. Valle,et al.  Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. , 2003, Journal of the American College of Cardiology.

[116]  F. Morady,et al.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. , 2003, Journal of the American College of Cardiology.

[117]  Ulrike Mende,et al.  Dilated Cardiomyopathy and Heart Failure Caused by a Mutation in Phospholamban , 2003, Science.

[118]  G. Danieli,et al.  Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. , 2002, American journal of human genetics.

[119]  M. S. Hamid,et al.  Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. , 2002, Journal of the American College of Cardiology.

[120]  J. Finsterer,et al.  Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. , 2002, The American journal of cardiology.

[121]  K. Kuck,et al.  Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.

[122]  K. Kuck,et al.  Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.

[123]  P. Kaufmann,et al.  Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy , 2001, Heart.

[124]  D. Kelsell,et al.  Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. , 2000, Human molecular genetics.

[125]  A. Crosby,et al.  Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease) , 2000, The Lancet.

[126]  R. Falk,et al.  Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. , 1997, Journal of the American College of Cardiology.

[127]  J. Perloff,et al.  Isolated noncompaction of left ventricular myocardium. A study of eight cases. , 1990, Circulation.

[128]  P. Eriksson,et al.  Pacemaker Treatment in Familial Amyloidosis with Polyneuropathy , 1984, Pacing and clinical electrophysiology : PACE.

[129]  D. Judge,et al.  Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. , 2018, Journal of cardiac failure.

[130]  H. Calkins,et al.  Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. , 2016, Heart rhythm.

[131]  J. Cigarroa,et al.  Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[132]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[133]  Roy J. Shephard,et al.  2011 Compendium of Physical Activities: A Second Update of Codes and MET Values , 2012 .

[134]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[135]  P. Eriksson,et al.  The sinoatrial node in familial amyloidosis with polyneuropathy , 2004, Virchows Archiv A.